within Pharmacolibrary.Drugs.ATC.C;

model C01AA05
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.7,
    Cl             = 0.0021666666666666666,
    adminDuration  = 600,
    adminMass      = 0.0005,
    adminCount     = 1,
    Vd             = 0.0050999999999999995,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.017333333333333333,
    Tlag           = 0
  );

  annotation(Documentation(
    info ="<html><body><p>Digoxin is a cardiac glycoside derived from the foxglove plant Digitalis lanata. It is primarily used in the treatment of various heart conditions, notably atrial fibrillation, atrial flutter, and sometimes heart failure that cannot be controlled by other medications. Digoxin is approved and widely used in clinical practice today.</p><h4>Pharmacokinetics</h4><p>Typical pharmacokinetic parameters for adult healthy volunteers after oral administration.</p><h4>References</h4><ol><li><p>Niemi, M, et al., &amp; Kivistö, KT (2003). Pharmacokinetic interactions with rifampicin : clinical relevance. <i>Clinical pharmacokinetics</i> 42(9) 819–850. DOI:<a href=&quot;https://doi.org/10.2165/00003088-200342090-00003&quot;>10.2165/00003088-200342090-00003</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/12882588/&quot;>https://pubmed.ncbi.nlm.nih.gov/12882588</a></p></li><li><p>Scheuenpflug, J, et al., &amp; Rübsamen-Schaeff, H (2022). The Effect of Oral Letermovir Administration on the Pharmacokinetics of a Single Oral Dose of P-Glycoprotein Substrate Digoxin in Healthy Volunteers. <i>Clinical pharmacology in drug development</i> 11(1) 6–15. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.1043&quot;>10.1002/cpdd.1043</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/34812580/&quot;>https://pubmed.ncbi.nlm.nih.gov/34812580</a></p></li><li><p>Bækdal, TA, et al., &amp; Anderson, TW (2019). Effect of Oral Semaglutide on the Pharmacokinetics of Lisinopril, Warfarin, Digoxin, and Metformin in Healthy Subjects. <i>Clinical pharmacokinetics</i> 58(9) 1193–1203. DOI:<a href=&quot;https://doi.org/10.1007/s40262-019-00756-2&quot;>10.1007/s40262-019-00756-2</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/30945118/&quot;>https://pubmed.ncbi.nlm.nih.gov/30945118</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end C01AA05;
